Inquiry Basket
| Catalog | Product Name | CAS Number |
|---|---|---|
| BADC-00347 | DM4 | 796073-69-3 |
| DM4 is an anti-tubulin agent that inhibits cell division. DM4 can be used to prepare antibody-drug conjugates. DM4 binds to tubulin at the maytansine-binding site, disrupting microtubule assembly/disassembly dynamics and inhibiting mitosis. | Inquiry | |
| BADC-00357 | Ansamitocin P-3 | 66584-72-3 |
| It is produced by the strain of Nocardia sp. C-15003(N-1). It has the function of anti-tumor, anti-plant pathogenic fungi, skin fungi and protozoa, and has no antibacterial activity. | Inquiry | |
| BADC-00360 | Tubulysin M | 936691-46-2 |
| Tubulysin M is a Tubulysin D analog with potential anti-cancer properties, used as the cytotoxic component in antibody-drug conjugates. | Inquiry | |
| BADC-00361 | Combretastatin A4 | 117048-59-6 |
| Combretastatin A4 is a stilbenoid isolated from Combretum caffrum. Combretastatin A4 was shown to inhibit tubulin polymerization (IC50 = 2.2 μM). It has demonstrable antineoplastic activity. | Inquiry | |
| BADC-00635 | MMAE-[d8] | 2070009-72-0 |
| MMAE-[d8] is a labelled analogue of MMAE, which is a potent mitotic inhibitor and a tubulin inhibitor. | Inquiry | |
| BADC-00687 | N-Me-L-Ala-maytansinol | 77668-69-0 |
| N-Me-L-Ala-maytansinol is a hydrophobic, cell permeable payload used in the preparation of antibody-drug conjugate (ADC). | Inquiry | |
| BADC-00714 | Maytansinol | 57103-68-1 |
| Maytansinol is an ansamacrolide isolated from P. verrucose. It was shown to inhibit microtubule assembly and induces microtubule disassembly in vitro. It exhibits antitumor activity. | Inquiry | |
| BADC-00723 | N-Acetyl-Calicheamicin | 108212-76-6 |
| N-Acetyl-Calicheamicin is a potent enediyne antitumor antibiotic that could be a potential cytotoxic DNA-binding agent in antibody-drug-conjugation (ADC). Calicheamicin is a naturally occurring hydrophobic enediyne antibiotic that was isolated from the actinomycete Micromonospora echinospora calichensis. | Inquiry | |
| BADC-00775 | FR-901464 | 146478-72-0 |
| It is a potent cell cycle inhibitor isolated from Pseudomonas sp. No.2663. It exhibits potent antitumor activities against tumor cell lines via binding to the spliceosome and modulating pre-mRNA splicing. | Inquiry | |
| BADC-00780 | Spliceostatin A | 391611-36-2 |
| Spliceostatin A is a potent inhibitor of in vitro and in vivo pre-mRNA splicing. It was shown to inhibit splicing and to interact with an essential component of the spliceosome, SF3b. Spliceostatin A is an inhibitor of RNA synthesis with excellent anticancer activity against a variety of human cancer cell lines. Spliceostatin A inhibits mitotic clone expansion and adipogenesis. | Inquiry | |
| BADC-00790 | Mithramycin A | 18378-89-7 |
| Mithramycin A is an antineoplastic antibiotic produced by Streptomyces plicatus. Mithramycin A is a polymerase inhibitor that binds to GC rich sequences located in the minor groove of DNA. | Inquiry | |
| BADC-00791 | Illudin S | 1149-99-1 |
| Illudin S is a natural sesquiterpene agent with strong anti-tumour activity. Illudin S inhibits DNA synthesis via an unknown mechanism. | Inquiry | |
| BADC-00798 | Actinomycin D | 50-76-0 |
| Actinomycin D is a chromopeptide antineoplastic antibiotic that exhibits high antibacterial and antitumor activity. Actinomycin D binds to single- and double-stranded DNA and subsequent inhibition of RNA and protein synthesis. | Inquiry | |
| BADC-00800 | Exatecan Mesylate | 169869-90-3 |
| Exatecan mesylate is a semisynthetic, water-soluble derivative of camptothecin with antineoplastic activity. Exatecan mesylate inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA and inhibiting the religation of DNA breaks, thereby inhibiting DNA replication and triggering apoptotic cell death. This agent does not require enzymatic activation and exhibits greater potency than camptothecin and other camptothecin analogs. | Inquiry | |
| BADC-01393 | Irinotecan EP Impurity E (SN-38) | 86639-52-3 |
| An impurity of Irinotecan, a Topoisomerase I inhibitor used for the treatment of colon cancer and small cell lung cancer. It inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. | Inquiry | |
| BADC-01394 | DXD | 1599440-33-1 |
| DXD, an Exatecan derivative for ADC, is a potent DNA topoisomerase I inhibitor with an IC50 of 0.31 μM. It can be used as a payload for antibody-conjugated drug ADCs targeting HER2. | Inquiry | |
| BADC-01397 | Chimmitecan | 185425-25-6 |
| Chimmitecan is a potent topoisomerase I inhibitor. Chimmitecan is also an active metabolite of simmitecan. Chimmitecan displays outstanding activity in vitro and in vivo. The substitution at the 9-position benefits chimmitecan a salient anti-MDR activity, stability in human serum albumin, improved solubility, and oral availability, which might favorably promise its therapeutic potential in clinical settings. | Inquiry | |
| BADC-01399 | Eribulin Mesylate | 441045-17-6 |
| Eribulin Mesylate is an antitumor drug that can be used to treat patients with metastatic breast cancer. It inhibits the proliferation of cancer cells by binding tubulin and microtubules. Eribulin Mesylate can inhibit experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. | Inquiry | |
| BADC-00001 | CBT-161 | |
| CBT-161 is an ADC that STI-A0602, the monoclonal antibody targeting c-Met, links tubulin inhibitors or DNA damaging agents via C-lock. Preclinical study showed that CBT-161 significantly inhibited tumor growth. | Inquiry | |
| BADC-00015 | MC-Val-Ala-PBD | 1342820-51-2 |
| MC-Val-Ala-PBD is a protective group conjugated PBD, PBD bind in the minor groove of DNA. | Inquiry |
